Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Evommune, Inc.NYSE: EVMN
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income grows 48.9% year over year
Q1 FY2026 net income of $21.67M (cash outflow) rose 48.9% year over year. Sequentially, it fell 23.3% from the prior quarter.
Context
- Net income amounted to 529.8% of revenue in FY2025, down 424.6 pp from a year earlier.
- Net income grew in size in 2 of the last 2 fiscal years.
- FY2025 was the largest annual figure in the 3 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of -$20.01M (-70.9%) for the fiscal year ending Dec 2026, a slowdown from the +3.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$21.67M-23.3% QoQ
- Last fiscal yearDec 2025
- -$68.87M+3.1% YoY
- LTMMar 2026
- -$75.99M— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +48.9% | +77.9% | +29.1 pp |
| 1 year | +3.1% | -70.9% | -74.0 pp |
| 3-year CAGR | — | -35.2% | — |
| 5-year CAGR | -19.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (68.87M) USD
- Year-over-year change
- -3.1%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (68.87M) | -3.1% |
| FY2024 | 2024-12-31 | (66.81M) | -96.2% |
| FY2023 | 2023-12-31 | (34.05M) | — |
Net Income vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 net income of $75.99M is the 6th largest of the 10 companies compared; the peer median is $54.29M.
- Net income amounts to 759.9% of revenue for EVMN, versus a peer median of 67.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $271.6M | +85.0% | +31.4% | 3566.6% | |
| LTM Jun 2026 | $197.22M | +360.0% | — | 67.9% | |
| LTM Mar 2026 | $194.97M | +211.8% | +5.9% | 129.0% | |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | $87.07M | +21.4% | +12.6% | — |
FTREFortrea Holdings Inc. | LTM Jun 2026 | $85.2M | -91.8% | — | 3.2% |
EVMNEvommune, Inc. | LTM Mar 2026 | $75.99M | — | — | 759.9% |
| LTM Mar 2026 | $54.29M | -11.4% | +42.6% | 187.8% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | $52.79M | -43.2% | +9.8% | — |
| LTM Sep 2026 | $43.31M | +168.3% | — | 16.3% | |
| LTM Mar 2026 | $31.99M | -57.0% | +9.4% | 41.0% | |
| Peer median (excluding EVMN) | $54.29M | +21.4% | +11.2% | 67.9% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| Deferred Income Tax | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 |
| Change in Working Capital | 3.34M | 7.42M | (4.12M) |
| Accounts Receivables | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 |
| Accounts Payables | 125K | 6.51M | (837K) |
| Other Working Capital | 3.22M | 918K | (3.28M) |
| Other Non-Cash Items | (261K) | (98K) | (4.84M) |
| Operating Cash Flow | (29.97M) | (58.2M) | (76.44M) |
| Capital Expenditures | (118K) | (88K) | (235K) |
| Acquisitions (Net) | 0 | 0 | 0 |
| Purchases of Investments | (91.31M) | (90.26M) | (199.17M) |
| Sales of Investments | 43M | 86.35M | 84.1M |
| Other Investing Activities | 0 | 0 | 0 |
| Investing Cash Flow | (48.43M) | (3.99M) | (115.31M) |
| Debt Repayment | 0 | 0 | (373K) |
| Common Stock Issued | 63.98M | 49.84M | 222.36M |
| Common Stock Repurchased | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 |
| Other Financing Activities | (230K) | (423K) | (1.22M) |
| Financing Cash Flow | 63.75M | 49.42M | 220.76M |
| Effect of Forex Changes | 43.67M | (1) | (1.21M) |
| Net Change in Cash | 29.02M | (12.77M) | 27.81M |
| Free Cash Flow | (30.09M) | (58.28M) | (76.68M) |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.